biote Corp.

biote Corp. (Nasdaq: BTMD) is a healthcare company specializing in bioidentical hormone optimization therapies that reached the public markets through a de-SPAC merger with Haymaker Acquisition Corp. III, sponsored by Haymaker Sponsor III LLC, which completed its SPAC IPO in 2021. The business combination closed in 2022, making biote a publicly traded entity in the healthcare services and medical wellness sector. The company, which trains and supports practitioners offering hormone pellet therapy, filed an 8-K with the SEC on May 14, 2025, reflecting ongoing reporting obligations as a post-merger public company. Sign up at SpacDesk for full filing history, sponsor data, and analytics on BTMD and hundreds of other SPAC transactions.